Table 77Overall survival for tandem HSCT and comparison (single HSCT) groups: CNS embryonal tumors

OutcomeTumor typeIntervention Tandem (%; ± 95% CI; SE) [N]Comparator Single (%; ± 95% CI; SE) [N]p ValueStudy
2-yearMB-PNET82 (59-100) [11]67 (13-100) [3]NRSung, 2007466
AT/RT[One patient alive without disease]Not applicableGidwani, 2008472
MB
AT/RT
Not applicable50 [4.5]
20 [1.2]*
Bandopadhayay, 2011479
3-yearMBNot applicable60 (36-84) [21]Chi, 2004475
AT/RTNot applicable23 (11) [13]Gardner, 2008476
5-yearMB-PNET82 (59-100) [11]NASung, 2007466
PNETNot applicable49 (33-62) [43]Fangusaro, 2008473
MBNot applicable70 (10) [21]Dhall, 2008474
MB50 [4.5]Not applicable<.01Bandopadhayay, 2011479
OS range for 5 years for studies with >10 patientsAll8249-70Not applicableNot applicable

AT/RT = atypical teratoid/rhabdoid tumor; CI = confidence interval; MB = medulloblastoma; N = number of patients; NA = not available; PNET = supratentorial primitive neuro-ectodermal tumors; SE = standard error

*

18-month OS.

From: Systematic Reviews

Cover of Hematopoietic Stem-Cell Transplantation in the Pediatric Population
Hematopoietic Stem-Cell Transplantation in the Pediatric Population [Internet].
Comparative Effectiveness Reviews, No. 48.
Ratko TA, Belinson SE, Brown HM, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.